March 17 Quick Takes: Tempus, Circle, Immatics, Exuma, CFIUS

Tempus raises $100M series G
Tempus raised $100 million in a series G round, bringing the total raised by the company to over $600 million since its founding in 2015. Baillie Gifford, Franklin Templeton, NEA, Novo Holdings, and funds and accounts managed by T. Rowe Price participated. The precision medicine company plans to expand its AI platform beyond oncology to disease areas including diabetes, depression and cardiology.

The Column Group leads $45M raise by Circle
Circle Pharma Inc. raised $45 million in a series B round led by The Column Group with participation by Nextech Invest, ShangPharma, LifeForce Capital, and the Berkeley Catalyst Fund. The oncology company will use the funds to develop cyclin inhibitors and to expand its pipeline of macrocycle-based therapeutics. The Column Group’s Peter Svennilson and Nextech’s Thilo Schroeder joined Circle’s board, and John Josey, who was CEO of Peloton Therapeutics Inc. until it was acquired by Merck & Co. Inc. (NYSE:MRK) last year, will serve as chairman...